WHO ICTRP trial
A study to evaluate CM24 in combination with nivolumab in adults with solid…
EUCTR2020-005016-21-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2020-005016-21-ES |
|---|---|
| Public title | A study to evaluate CM24 in combination with nivolumab in adults with solid tumours |
| Scientific title | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumours |
| Primary sponsor | Famewave Ltd. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;Spain;Israel |
| Conditions | Part A- Recurrent and metastatic non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma Part B- Recurrent or metastatic immune checkpoint refractory NSCLC Part… |
| Interventions | Product Code: CM24 Pharmaceutical Form: Solution for infusion INN or Proposed INN: CM24 Other descriptive name: Humanised IgG4k monoclonal antibody against Carcinoembryonic antigen-related cell adhesion molecule 1 Concentration unit: mg/ml… |
| Registration date | Jul 30, 2021 |
| Target size | 74 |
| Secondary IDs | FW-2020-1 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: